{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030816","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.962590+00:00","generated_at":"2026-05-17T04:04:46.366398+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study","bullets":["All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.","Average total ablation time of 50 seconds with 13 applications; no esophageal or phrenic nerve damage reported.","No ablation-related severe or major adverse events in 44 treated patients across three European sites.","CEO confirms on track to initiate IDE study this year for nPulse Cardiac Surgical System."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030816","json":"https://secwatch.observer/filing/0001437749-25-030816.json","markdown":"https://secwatch.observer/filing/0001437749-25-030816.md","text":"https://secwatch.observer/filing/0001437749-25-030816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/0001437749-25-030816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/plse20251009_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:04:46.366398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}